Trial Profile
Efficacy and Tolerability of a New Extended-Release Formulation of Nicotinic Acid in Korean Adults With Mixed Dyslipidemia: An 8-Week, Multicenter, Prospective, Randomized, Double-Blind, and Placebo-Controlled Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Oct 2011
Price :
$35
*
At a glance
- Drugs Niacin (Primary)
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- 24 Oct 2011 New trial record